M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

Vaccine
Richard T WiedmannLuwy K Musey

Abstract

Prior to 2006, M-M-R(®)II (measles, mumps, and rubella virus vaccine live) was manufactured using human serum albumin (HSA) and each dose of the vaccine contained a relatively small amount (≤0.3mg) of HSA. Because of specific regulatory requirements and limited suppliers of HSA acceptable for human use, there was a need to replace HSA with recombinant human albumin (rHA) to mitigate any potential risk to the availability of M-M-R(®)II. Two different formulations of M-M-R(®)II manufactured using either rHA or HSA were clinically evaluated for safety and immunogenicity when administered as a 2-dose regimen to healthy children 12-18 months and 3-4 years of age. Adverse events, including those indicative of a possible hypersensitivity reaction, were collected for 42 days after each dose. Antibodies to measles, mumps, and rubella were measured before and approximately 6 weeks after dose 1. Antibodies to rHA were measured before and approximately 6 weeks after dose 1 and dose 2. Antibody seroconversion rates to measles, mumps, and rubella were 97.0%, 99.5%, and 99.7%, respectively, for recipients of M-M-R(®)II with rHA and 97.2%, 97.9%, and 99.6%, respectively, for recipients of M-M-R(®)II with HSA, and geometric mean titers to all 3...Continue Reading

References

Oct 1, 1975·Clinical Pediatrics·V W WaltersM T Kenny
Apr 1, 1985·Statistics in Medicine·O Miettinen, M Nurminen
Aug 7, 1999·Revista Do Instituto De Medicina Tropical De São Paulo·G GonçalvesH R Andrade
Jun 16, 2000·Applied Microbiology and Biotechnology·H A KangS K Rhee
Feb 15, 2002·The New England Journal of Medicine·Nicole CasadevallPatrick Mayeux
Apr 23, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·C RothschildW Effenberger
Dec 17, 2004·Journal of Clinical Pharmacology·Dietrich BosseFritz Schindel
Aug 12, 2005·The Pediatric Infectious Disease Journal·Henry ShinefieldUNKNOWN Dose Selection Study Group for Proquad
Feb 9, 2006·Biologicals : Journal of the International Association of Biological Standardization·Kaoru Kobayashi
Mar 28, 2012·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Centers for Disease Control and Prevention, Public Health Service, U.S. Department Health

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.